SG10201700961TA - Methods and compositions for the targeted modification of a genome - Google Patents
Methods and compositions for the targeted modification of a genomeInfo
- Publication number
- SG10201700961TA SG10201700961TA SG10201700961TA SG10201700961TA SG10201700961TA SG 10201700961T A SG10201700961T A SG 10201700961TA SG 10201700961T A SG10201700961T A SG 10201700961TA SG 10201700961T A SG10201700961T A SG 10201700961TA SG 10201700961T A SG10201700961T A SG 10201700961TA
- Authority
- SG
- Singapore
- Prior art keywords
- genome
- compositions
- methods
- targeted modification
- targeted
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1024—In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
- C12N2999/007—Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361914768P | 2013-12-11 | 2013-12-11 | |
US201462017416P | 2014-06-26 | 2014-06-26 | |
US201462029261P | 2014-07-25 | 2014-07-25 | |
US201462052906P | 2014-09-19 | 2014-09-19 | |
US201462059527P | 2014-10-03 | 2014-10-03 | |
US201462064384P | 2014-10-15 | 2014-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201700961TA true SG10201700961TA (en) | 2017-04-27 |
Family
ID=51830654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201700961TA SG10201700961TA (en) | 2013-12-11 | 2014-10-15 | Methods and compositions for the targeted modification of a genome |
Country Status (12)
Country | Link |
---|---|
US (7) | US9546384B2 (en) |
JP (3) | JP6174811B2 (en) |
KR (2) | KR102170502B1 (en) |
CN (2) | CN105980568B (en) |
AU (3) | AU2014360811B2 (en) |
BR (1) | BR112016013400B1 (en) |
CA (1) | CA2933433C (en) |
IL (1) | IL245674B (en) |
MX (2) | MX2016007654A (en) |
RU (2) | RU2685914C1 (en) |
SG (1) | SG10201700961TA (en) |
WO (1) | WO2015088643A1 (en) |
Families Citing this family (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
US9217040B2 (en) | 2011-01-14 | 2015-12-22 | The Regents Of The University Of California | Therapeutic antibodies against ROR-1 protein and methods for use of same |
EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
WO2013163394A1 (en) | 2012-04-25 | 2013-10-31 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
PT2800811T (en) | 2012-05-25 | 2017-08-17 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
EP2888283B1 (en) | 2012-08-24 | 2018-09-19 | The Regents of The University of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
ES2769310T3 (en) | 2012-12-06 | 2020-06-25 | Sigma Aldrich Co Llc | Modification and regulation of the genome based on CRISPR |
RU2690352C2 (en) | 2013-02-20 | 2019-05-31 | Регенерон Фармасютикалс, Инк. | Genetic modification of rats |
CN110540991B (en) | 2013-03-15 | 2023-10-24 | 通用医疗公司 | Enhancement of specificity of RNA-guided genome editing using truncated guide RNA (tru-gRNA) |
US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
WO2014204578A1 (en) | 2013-06-21 | 2014-12-24 | The General Hospital Corporation | Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing |
JP6411463B2 (en) | 2013-04-16 | 2018-10-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
WO2015040402A1 (en) * | 2013-09-18 | 2015-03-26 | Kymab Limited | Methods. cells & organisms |
AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
US10787684B2 (en) | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
RU2685914C1 (en) * | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Methods and compositions for genome targeted modification |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
CN106133141B (en) | 2014-01-08 | 2021-08-20 | 哈佛学院董事及会员团体 | RNA-guided gene driving |
EP3102722B1 (en) | 2014-02-04 | 2020-08-26 | Jumpcode Genomics, Inc. | Genome fractioning |
PL3105328T3 (en) | 2014-02-11 | 2020-10-19 | The Regents Of The University Of Colorado, A Body Corporate | Crispr enabled multiplexed genome engineering |
MX2020004803A (en) * | 2014-05-30 | 2021-10-13 | Regeneron Pharma | Humanized dipeptidyl peptidase iv (dpp4) animals. |
PL3152312T3 (en) | 2014-06-06 | 2020-08-10 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for modifying a targeted locus |
MX2016017317A (en) | 2014-06-26 | 2017-08-24 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use. |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10428310B2 (en) | 2014-10-15 | 2019-10-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
WO2016065341A1 (en) | 2014-10-24 | 2016-04-28 | Avectas Limited | Delivery across cell plasma membranes |
US11680268B2 (en) | 2014-11-07 | 2023-06-20 | Editas Medicine, Inc. | Methods for improving CRISPR/Cas-mediated genome-editing |
WO2016081924A1 (en) * | 2014-11-20 | 2016-05-26 | Duke University | Compositions, systems and methods for cell therapy |
KR102531016B1 (en) | 2014-11-21 | 2023-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs |
RU2707137C2 (en) | 2014-12-19 | 2019-11-22 | Регенерон Фармасьютикалз, Инк. | Methods and compositions for targeted genetic modification by single-step multiple targeting |
WO2016138292A1 (en) | 2015-02-25 | 2016-09-01 | Igenomx International Genomics Corporation | Methods and compositions for in silico long read sequencing |
RU2744831C2 (en) | 2015-03-16 | 2021-03-16 | Регенерон Фармасьютикалз, Инк. | Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception |
ES2905525T3 (en) | 2015-05-06 | 2022-04-11 | Snipr Tech Ltd | Alteration of microbial populations and modification of the microbiota |
EP3310159A4 (en) | 2015-06-16 | 2019-02-20 | The Jackson Laboratory | Genetically modified non-human animals and methods relating to complement dependent cytotoxicity |
WO2017004261A1 (en) | 2015-06-29 | 2017-01-05 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
AU2016301195B2 (en) | 2015-08-06 | 2022-09-01 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses |
US9926546B2 (en) | 2015-08-28 | 2018-03-27 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
WO2017040348A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Engineered crispr-cas9 nucleases |
CA2998894A1 (en) | 2015-09-18 | 2017-03-23 | The Regents Of The University Of California | Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof |
KR102645625B1 (en) * | 2015-09-22 | 2024-03-07 | 제넨테크, 인크. | Expression of Fc-containing proteins |
AU2016326711B2 (en) | 2015-09-24 | 2022-11-03 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/Cas-mediated genome editing |
IL294014B1 (en) | 2015-10-23 | 2024-03-01 | Harvard College | Nucleobase editors and uses thereof |
JP2018532415A (en) * | 2015-11-06 | 2018-11-08 | ザ ジャクソン ラボラトリー | Large genomic DNA knock-ins and uses thereof |
WO2017096041A1 (en) * | 2015-12-02 | 2017-06-08 | The Regents Of The University Of California | Compositions and methods for modifying a target nucleic acid |
CA3009715A1 (en) | 2015-12-30 | 2017-07-06 | Avectas Limited | Vector-free delivery of gene editing proteins and compositions to cells and tissues |
CA3013932A1 (en) * | 2016-02-12 | 2017-08-17 | Jumpcode Genomics, Inc. | Method for target specific rna transcription of dna sequences |
US11339427B2 (en) | 2016-02-12 | 2022-05-24 | Jumpcode Genomics, Inc. | Method for target specific RNA transcription of DNA sequences |
EP3219799A1 (en) | 2016-03-17 | 2017-09-20 | IMBA-Institut für Molekulare Biotechnologie GmbH | Conditional crispr sgrna expression |
EP3433363A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
IL299000A (en) * | 2016-04-04 | 2023-02-01 | Eth Zuerich | Mammalian Cell Line for Protein Production and Library Generation |
US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
WO2017189336A1 (en) * | 2016-04-25 | 2017-11-02 | The Regents Of The University Of California | Methods and compositions for genomic editing |
EP3457840B1 (en) * | 2016-05-20 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Methods for breaking immunological tolerance using multiple guide rnas |
CN113907043B (en) | 2016-06-03 | 2023-08-01 | 瑞泽恩制药公司 | Non-human animals expressing exogenous terminal deoxynucleotidyl transferase |
GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
AU2017280353B2 (en) | 2016-06-24 | 2021-11-11 | Inscripta, Inc. | Methods for generating barcoded combinatorial libraries |
US10688181B2 (en) | 2016-06-27 | 2020-06-23 | The Regents Of The University Of California | Cancer treatment combinations |
EP3490373B1 (en) | 2016-07-29 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Mice comprising mutations resulting in expression of c-truncated fibrillin-1 |
JP7184364B2 (en) * | 2016-08-02 | 2022-12-06 | 国立大学法人京都大学 | Methods for genome editing |
AU2017306676B2 (en) | 2016-08-03 | 2024-02-22 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN110214180A (en) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | The AAV of nucleobase editing machine is delivered |
CN106544360B (en) * | 2016-10-17 | 2019-11-05 | 扬州大学 | A method of terminating the transcription of lncRNA diallele |
US20190390221A1 (en) * | 2016-11-02 | 2019-12-26 | David Kiewlich | Plasmid vectors for expression of large nucleic acid transgenes |
DK3766343T3 (en) | 2016-11-04 | 2022-06-20 | Regeneron Pharma | Non-human animals with a engineered immunoglobulin lambda light chain locus |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
AU2018210420A1 (en) | 2017-01-19 | 2019-08-08 | Omniab, Inc. | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
JP7227912B2 (en) | 2017-02-08 | 2023-02-24 | ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド | Regulation of chimeric antigen receptors |
EP3583201B1 (en) * | 2017-02-14 | 2024-01-17 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Methods of engineering human induced pluripotent stem cells to produce liver tissue |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
JP2020510439A (en) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Base-editing factor from cytosine to guanine |
KR20190130613A (en) | 2017-03-23 | 2019-11-22 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Nucleobase edits comprising nucleic acid programmable DNA binding proteins |
CN106987604B (en) * | 2017-03-29 | 2021-05-28 | 北京希诺谷生物科技有限公司 | Method for preparing atherosclerosis disease model dog |
EP3612551A4 (en) | 2017-04-21 | 2020-12-30 | The General Hospital Corporation | Variants of cpf1 (cas12a) with altered pam specificity |
WO2018197520A1 (en) * | 2017-04-24 | 2018-11-01 | Dupont Nutrition Biosciences Aps | Methods and compositions of anti-crispr proteins for use in plants |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
JP2020521446A (en) | 2017-05-25 | 2020-07-27 | ザ ジェネラル ホスピタル コーポレイション | Bipartite base editor (BBE) structure and type II-C-CAS9 zinc finger editing |
CN109136273B (en) * | 2017-06-16 | 2022-09-27 | 中国科学院分子细胞科学卓越创新中心 | Method for preparing immunodeficient rat and application thereof |
RU2020100919A (en) * | 2017-06-20 | 2021-07-20 | Цзянсу Хэнжуй Медсин Ко., Лтд. | METHOD FOR NOCOUTING TARGET GENE IN T-CELL IN VITRO AND CRRNA, USED IN THIS METHOD |
US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
US11696572B2 (en) | 2017-06-27 | 2023-07-11 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ASGR1 locus |
HRP20220615T1 (en) | 2017-06-30 | 2022-06-24 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
WO2019018534A1 (en) | 2017-07-18 | 2019-01-24 | The Board Of Trustees Of Leland Stanford Junior University | Scarless genome editing through two-step homology directed repair |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
JP2020533957A (en) | 2017-07-31 | 2020-11-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | CRISPR Reporter Non-Human Animals and Their Use |
BR112019027673A2 (en) | 2017-07-31 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | non-human animal, and, methods to test the recombination induced by crispr / cas and to optimize the ability of crispr / cas |
KR20200032693A (en) | 2017-07-31 | 2020-03-26 | 리제너론 파마슈티칼스 인코포레이티드 | Cas-transformed mouse embryonic stem cells and mice and uses thereof |
US20190045761A1 (en) * | 2017-08-11 | 2019-02-14 | Recombinetics, Inc. | Inducible disease models methods of making them and use in tissue complementation |
US10738327B2 (en) | 2017-08-28 | 2020-08-11 | Inscripta, Inc. | Electroporation cuvettes for automation |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
EP3679143A1 (en) * | 2017-09-08 | 2020-07-15 | Life Technologies Corporation | Methods for improved homologous recombination and compositions thereof |
AU2018338790B2 (en) | 2017-09-29 | 2022-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TTR locus and methods of use |
CA3074927A1 (en) | 2017-09-30 | 2019-04-04 | Inscripta, Inc. | Flow through electroporation instrumentation |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
KR102444458B1 (en) | 2017-11-10 | 2022-09-19 | 리제너론 파마슈티칼스 인코포레이티드 | Non-Human Animals Containing the SLC30A8 Mutation and Methods of Use |
SG11202002456WA (en) * | 2017-11-30 | 2020-04-29 | Regeneron Pharma | Non-human animals comprising a humanized trkb locus |
US11643670B2 (en) | 2018-01-29 | 2023-05-09 | Massachusetts Institute Of Technology | Methods of enhancing chromosomal homologous recombination |
KR102647714B1 (en) | 2018-03-19 | 2024-03-18 | 리제너론 파마슈티칼스 인코포레이티드 | Transcriptional regulation in animals using the CRISPR/Cas system |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
AU2019242586A1 (en) | 2018-03-26 | 2020-10-01 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
CN112204131A (en) | 2018-03-29 | 2021-01-08 | 因思科瑞普特公司 | Automated control of cell growth rate for induction and transformation |
US10376889B1 (en) | 2018-04-13 | 2019-08-13 | Inscripta, Inc. | Automated cell processing instruments comprising reagent cartridges |
US10557216B2 (en) | 2018-04-24 | 2020-02-11 | Inscripta, Inc. | Automated instrumentation for production of T-cell receptor peptide libraries |
US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
WO2019209926A1 (en) | 2018-04-24 | 2019-10-31 | Inscripta, Inc. | Automated instrumentation for production of peptide libraries |
EP3794130A4 (en) | 2018-05-16 | 2022-07-27 | Synthego Corporation | Methods and systems for guide rna design and use |
US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
US10532324B1 (en) | 2018-08-14 | 2020-01-14 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
US10752874B2 (en) | 2018-08-14 | 2020-08-25 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
IL292273B2 (en) | 2018-08-14 | 2023-10-01 | Inscripta Inc | Instruments, modules, and methods for improved detection of edited sequences in live cells |
EP3844263A4 (en) | 2018-08-30 | 2022-05-25 | Inscripta, Inc. | Improved detection of nuclease edited sequences in automated modules and instruments |
WO2020056122A1 (en) | 2018-09-13 | 2020-03-19 | Regeneron Pharmaceuticals, Inc. | Complement factor h gene knockout rat as a model of c3 glomerulopathy |
US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
WO2020086475A1 (en) | 2018-10-22 | 2020-04-30 | Inscripta, Inc. | Engineered enzymes |
US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
US11965172B2 (en) | 2018-11-05 | 2024-04-23 | California Institute Of Technology | DNA sequence modification-based gene drive |
CN111321171A (en) * | 2018-12-14 | 2020-06-23 | 江苏集萃药康生物科技有限公司 | Method for preparing gene targeting animal model by applying CRISPR/Cas9 mediated ES targeting technology |
JP7449291B2 (en) | 2018-12-20 | 2024-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Nuclease-mediated repeat expansion |
JP7144618B2 (en) * | 2018-12-20 | 2022-09-29 | 北京大学 | Compositions and methods for efficient genetic screening using barcoded guide RNA constructs |
US11946040B2 (en) | 2019-02-04 | 2024-04-02 | The General Hospital Corporation | Adenine DNA base editor variants with reduced off-target RNA editing |
WO2020168315A1 (en) | 2019-02-15 | 2020-08-20 | Just-Evotec Biologics, Inc. | Automated biomanufacturing systems, facilities, and processes |
NL2022714B1 (en) * | 2019-03-11 | 2020-09-18 | Academisch Ziekenhuis Leiden | Optimised RAG1 deficient SCID Gene Therapy |
EP3942040A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
CN113631713A (en) | 2019-03-25 | 2021-11-09 | 因思科瑞普特公司 | Simultaneous multiplex genome editing in yeast |
SG11202108454RA (en) | 2019-04-04 | 2021-09-29 | Regeneron Pharma | Non-human animals comprising a humanized coagulation factor 12 locus |
CN113966401A (en) * | 2019-04-10 | 2022-01-21 | 犹他大学研究基金会 | HTRA1 modulation for the treatment of AMD |
EP3978607A4 (en) * | 2019-05-27 | 2023-01-25 | Transgenic Inc. | Exon-humanized mouse |
KR20220016869A (en) | 2019-06-04 | 2022-02-10 | 리제너론 파마슈티칼스 인코포레이티드 | Non-Human Animals Comprising a Humanized TTR Locus with Beta-Slip Mutations and Methods of Use |
CA3139122C (en) | 2019-06-06 | 2023-04-25 | Inscripta, Inc. | Curing for recursive nucleic acid-guided cell editing |
MX2021015122A (en) | 2019-06-07 | 2022-04-06 | Regeneron Pharma | Non-human animals comprising a humanized albumin locus. |
US10907125B2 (en) | 2019-06-20 | 2021-02-02 | Inscripta, Inc. | Flow through electroporation modules and instrumentation |
CN114008070A (en) | 2019-06-21 | 2022-02-01 | 因思科瑞普特公司 | Whole genome rationally designed mutations leading to increased lysine production in E.coli |
US10927385B2 (en) | 2019-06-25 | 2021-02-23 | Inscripta, Inc. | Increased nucleic-acid guided cell editing in yeast |
WO2021102059A1 (en) | 2019-11-19 | 2021-05-27 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
WO2021118626A1 (en) | 2019-12-10 | 2021-06-17 | Inscripta, Inc. | Novel mad nucleases |
US10704033B1 (en) | 2019-12-13 | 2020-07-07 | Inscripta, Inc. | Nucleic acid-guided nucleases |
KR20220118498A (en) | 2019-12-18 | 2022-08-25 | 인스크립타 인코포레이티드 | Cascade/DCAS3 Complementary Assay for In Vivo Detection of Nucleic Acid-Guided Nuclease Edited Cells |
US10689669B1 (en) | 2020-01-11 | 2020-06-23 | Inscripta, Inc. | Automated multi-module cell processing methods, instruments, and systems |
AU2021213705A1 (en) | 2020-01-27 | 2022-06-16 | Inscripta, Inc. | Electroporation modules and instrumentation |
US20210227812A1 (en) | 2020-01-28 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
EP4099821A1 (en) | 2020-02-07 | 2022-12-14 | Regeneron Pharmaceuticals, Inc. | <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use |
US20230102342A1 (en) | 2020-03-23 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
EP4134431A4 (en) * | 2020-04-06 | 2024-06-05 | Logomix, Inc. | Genome alteration method and genome alteration kit |
US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
MX2022014008A (en) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence. |
US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
BR112022024652B1 (en) * | 2020-06-06 | 2024-01-16 | Lanzatech, Inc | GENETICALLY MODIFIED MICRO-ORGANISM, AND METHOD FOR PRODUCING A PRODUCT |
CN111647663B (en) * | 2020-06-18 | 2022-07-01 | 安徽农业大学 | Molecular genetic marker for chicken walking number character and application |
WO2021263146A2 (en) | 2020-06-26 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
WO2022060749A1 (en) | 2020-09-15 | 2022-03-24 | Inscripta, Inc. | Crispr editing to embed nucleic acid landing pads into genomes of live cells |
US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
EP4271802A1 (en) | 2021-01-04 | 2023-11-08 | Inscripta, Inc. | Mad nucleases |
WO2022150269A1 (en) | 2021-01-07 | 2022-07-14 | Inscripta, Inc. | Mad nucleases |
WO2022154343A1 (en) * | 2021-01-13 | 2022-07-21 | 재단법인대구경북과학기술원 | Alzheimer-resistant cell model including apoe christchurch mutation and construction method therefor |
JP2024505524A (en) | 2021-01-29 | 2024-02-06 | メルク・シャープ・アンド・ドーム・エルエルシー | Compositions of programmed death receptor 1 (PD-1) antibodies and methods for obtaining the compositions |
US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
CA3212642A1 (en) | 2021-03-05 | 2022-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | In vivo dna assembly and analysis |
EP4370647A1 (en) | 2021-07-15 | 2024-05-22 | Just-Evotec Biologics, Inc. | Bidirectional tangential flow filtration (tff) perfusion system |
CN118251491A (en) | 2021-10-28 | 2024-06-25 | 瑞泽恩制药公司 | CRISPR/Cas related methods and compositions for knockout of C5 |
AU2022381205A1 (en) | 2021-11-04 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified cacng1 locus |
CA3238939A1 (en) | 2021-12-08 | 2023-06-15 | Gaurang Patel | Mutant myocilin disease model and uses thereof |
US20230279442A1 (en) | 2021-12-15 | 2023-09-07 | Versitech Limited | Engineered cas9-nucleases and method of use thereof |
WO2023122506A1 (en) | 2021-12-20 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
WO2023154861A1 (en) | 2022-02-11 | 2023-08-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for screening 4r tau targeting agents |
WO2023235725A2 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr-based therapeutics for c9orf72 repeat expansion disease |
WO2024026488A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified transferrin receptor locus |
WO2024031053A1 (en) | 2022-08-05 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Aggregation-resistant variants of tdp-43 |
WO2024073679A1 (en) | 2022-09-29 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
Family Cites Families (224)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
DE19525285C2 (en) | 1995-06-28 | 1999-04-15 | Inst Pflanzengenetik & Kultur | In vitro test procedure for the detection of chemical-induced embryotoxic / teratogenic effects |
EP0880584A1 (en) | 1996-02-16 | 1998-12-02 | University Of Edinburgh | Cytokine expressed by dia/lif-deficient embryonic stem cells for the inhibition of differentiation |
US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
US6136566A (en) | 1996-10-04 | 2000-10-24 | Lexicon Graphics Incorporated | Indexed library of cells containing genomic modifications and methods of making and utilizing the same |
AU8587598A (en) | 1997-07-26 | 1999-02-16 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
WO2000039316A1 (en) | 1998-12-31 | 2000-07-06 | The J. David Gladstone Institutes | Transgenic rodents and rodent cell lines expressing hiv co-receptors |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
AU2982900A (en) | 1999-02-03 | 2000-08-25 | Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
US20030104526A1 (en) | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
ATE309536T1 (en) | 1999-12-06 | 2005-11-15 | Sangamo Biosciences Inc | METHODS OF USING RANDOMIZED ZINC FINGER PROTEIN LIBRARIES TO IDENTIFY GENE FUNCTIONS |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2884102A (en) | 2000-12-07 | 2002-06-18 | Sangamo Biosciences Inc | Regulation of angiogenesis with zinc finger proteins |
CA2435394C (en) | 2001-01-22 | 2018-01-09 | Sangamo Biosciences, Inc. | Modified zinc finger binding proteins |
AU2002225187A1 (en) | 2001-01-22 | 2002-07-30 | Sangamo Biosciences, Inc. | Zinc finger polypeptides and their use |
AUPR451401A0 (en) | 2001-04-20 | 2001-05-24 | Monash University | A method of nuclear transfer |
AU2003251286B2 (en) | 2002-01-23 | 2007-08-16 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
US20060078552A1 (en) | 2002-03-15 | 2006-04-13 | Sylvain Arnould | Hybrid and single chain meganucleases and use thereof |
US20030232410A1 (en) | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US7612250B2 (en) | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
CA2497913C (en) | 2002-09-05 | 2014-06-03 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
AU2003290518A1 (en) | 2002-09-06 | 2004-04-23 | Fred Hutchinson Cancer Research Center | Methods and compositions concerning designed highly-specific nucleic acid binding proteins |
US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
US7344886B2 (en) | 2002-11-29 | 2008-03-18 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
AU2004204509A1 (en) | 2003-01-13 | 2004-07-29 | Mario R. Capecchi | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
WO2005001087A2 (en) | 2003-06-11 | 2005-01-06 | Regeneron Pharmaceuticals, Inc. | Methods of modifying genes in eukaryotic cells |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
JP4862119B2 (en) | 2004-03-04 | 2012-01-25 | 大日本住友製薬株式会社 | Rat embryonic stem cells |
EP1591521A1 (en) | 2004-04-30 | 2005-11-02 | Cellectis | I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof |
WO2006028723A1 (en) | 2004-09-03 | 2006-03-16 | Moraga Biotechnology Inc. | Non-embryonic totipotent blastomer-like stem cells and methods therefor |
CA2579677A1 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
DK2767161T3 (en) | 2004-10-19 | 2018-05-07 | Regeneron Pharma | Method of generating an animal homozygous for genetic modification |
FR2879622B1 (en) | 2004-12-17 | 2008-02-01 | Agronomique Inst Nat Rech | IN VITRO PROCESS FOR THE PRODUCTION OF OOCYTES OR EGGS WITH TARGETED GENOMIC MODIFICATION |
AU2006224248B2 (en) | 2005-03-15 | 2011-01-06 | Cellectis | I-Crei meganuclease variants with modified specificity, method of preparation and uses thereof |
WO2006097784A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
AU2007232393A1 (en) | 2006-03-30 | 2007-10-11 | The University Court Of The University Of Edinburgh | Culture medium containing kinase inhibitors. and uses thereof |
WO2007117410A2 (en) | 2006-03-31 | 2007-10-18 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
CN101117633B (en) | 2006-08-03 | 2011-07-20 | 上海交通大学附属儿童医院 | Nucleus transplantation method |
JP5632610B2 (en) | 2006-12-14 | 2014-11-26 | ダウ アグロサイエンシィズ エルエルシー | Optimized non-canonical zinc finger protein |
US7771967B2 (en) | 2006-12-22 | 2010-08-10 | The J. David Gladstone Institutes | Nucleic acid encoding apolipoprotein E-I3 |
US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
WO2008133938A2 (en) | 2007-04-26 | 2008-11-06 | Sangamo Biosciences, Inc. | Targeted integration into the ppp1r12c locus |
CN101784664B (en) | 2007-06-01 | 2013-04-10 | Omt公司 | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
AU2008335178A1 (en) | 2007-12-10 | 2009-06-18 | Ablexis Llc | Methods for sequential replacement of targeted region by homologous recombination |
KR101759586B1 (en) | 2008-08-22 | 2017-07-19 | 상가모 테라퓨틱스, 인코포레이티드 | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US20100076057A1 (en) * | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
EP2180058A1 (en) | 2008-10-23 | 2010-04-28 | Cellectis | Meganuclease recombination system |
KR101803737B1 (en) | 2008-12-04 | 2017-12-01 | 상가모 테라퓨틱스, 인코포레이티드 | Genome editing in rats using zinc-finger nucleases |
US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
JP5932632B2 (en) | 2009-03-20 | 2016-06-15 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Modification of CXCR4 using modified zinc finger protein |
US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US20120178647A1 (en) | 2009-08-03 | 2012-07-12 | The General Hospital Corporation | Engineering of zinc finger arrays by context-dependent assembly |
US8518392B2 (en) | 2009-08-14 | 2013-08-27 | Regeneron Pharmaceuticals, Inc. | Promoter-regulated differentiation-dependent self-deleting cassette |
US10913929B2 (en) | 2009-10-13 | 2021-02-09 | Stemcell Technologies Inc. | Method of differentiating stem cells |
WO2011051390A1 (en) | 2009-10-28 | 2011-05-05 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Homologous recombination in the oocyte |
CA2779858C (en) | 2009-10-29 | 2019-10-29 | Aris N. Economides | Multifunctional alleles |
US20120315670A1 (en) | 2009-11-02 | 2012-12-13 | Gen9, Inc. | Compositions and Methods for the Regulation of Multiple Genes of Interest in a Cell |
JP5807862B2 (en) | 2009-12-01 | 2015-11-10 | 国立研究開発法人国立がん研究センター | Preparation of chimeric rat using rat embryonic stem cells |
WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
JP5924773B2 (en) | 2009-12-21 | 2016-05-25 | キージーン・エン・フェー | Improved technique for transfection of protoplasts |
SG181690A1 (en) | 2009-12-21 | 2012-07-30 | Regeneron Pharma | Humanized fcy r mice |
NZ600546A (en) | 2010-01-22 | 2014-08-29 | Dow Agrosciences Llc | Excision of transgenes in genetically modified organisms |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
EP2660318A1 (en) | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
GB201009732D0 (en) | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
CA2800534C (en) | 2010-06-11 | 2019-01-22 | Regeneron Pharmaceuticals, Inc. | Production of fertile xy female animals from xy es cells |
CA2993567C (en) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
WO2012018726A1 (en) | 2010-08-02 | 2012-02-09 | Cellectis Sa | Method for increasing double-strand break-induced gene targeting |
US9528124B2 (en) | 2013-08-27 | 2016-12-27 | Recombinetics, Inc. | Efficient non-meiotic allele introgression |
WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
WO2012168307A2 (en) | 2011-06-07 | 2012-12-13 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Improved recombination efficiency by inhibition of nhej dna repair |
AU2012327204B2 (en) | 2011-10-28 | 2016-01-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified T cell receptor mice |
GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
WO2013163394A1 (en) | 2012-04-25 | 2013-10-31 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
CN104471067B (en) | 2012-05-07 | 2020-08-14 | 桑格摩生物治疗股份有限公司 | Methods and compositions for nuclease-mediated targeted integration of transgenes |
PT2800811T (en) | 2012-05-25 | 2017-08-17 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
WO2013188522A2 (en) | 2012-06-12 | 2013-12-19 | Genentech, Inc. | Methods and compositions for generating conditional knock-out alleles |
EP3494997B1 (en) | 2012-07-25 | 2019-09-18 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
CN110643600A (en) | 2012-10-23 | 2020-01-03 | 基因工具股份有限公司 | System for cutting target DNA and use thereof |
ES2769310T3 (en) | 2012-12-06 | 2020-06-25 | Sigma Aldrich Co Llc | Modification and regulation of the genome based on CRISPR |
WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
EP4279588A3 (en) | 2012-12-12 | 2024-01-17 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
MX2015007550A (en) | 2012-12-12 | 2017-02-02 | Broad Inst Inc | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications. |
US20140186843A1 (en) | 2012-12-12 | 2014-07-03 | Massachusetts Institute Of Technology | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
EP2931892B1 (en) | 2012-12-12 | 2018-09-12 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
EP3825401A1 (en) | 2012-12-12 | 2021-05-26 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
SG10201912327SA (en) | 2012-12-12 | 2020-02-27 | Broad Inst Inc | Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation |
WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
EP3553174A1 (en) | 2012-12-17 | 2019-10-16 | President and Fellows of Harvard College | Rna-guided human genome engineering |
JP6583918B2 (en) | 2012-12-27 | 2019-10-02 | キージーン ナムローゼ フェンノートシャップ | Methods for breaking genetic linkages in plants |
WO2014127287A1 (en) | 2013-02-14 | 2014-08-21 | Massachusetts Institute Of Technology | Method for in vivo tergated mutagenesis |
RU2690352C2 (en) | 2013-02-20 | 2019-05-31 | Регенерон Фармасютикалс, Инк. | Genetic modification of rats |
WO2014130955A1 (en) | 2013-02-25 | 2014-08-28 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
JP2016507244A (en) | 2013-02-27 | 2016-03-10 | ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト(ゲーエムベーハー)Helmholtz Zentrum MuenchenDeutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH) | Gene editing in oocytes by Cas9 nuclease |
US10612043B2 (en) | 2013-03-09 | 2020-04-07 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events |
ES2901396T3 (en) | 2013-03-14 | 2022-03-22 | Caribou Biosciences Inc | Nucleic Acid Targeting Nucleic Acid Compositions and Methods |
WO2014204578A1 (en) | 2013-06-21 | 2014-12-24 | The General Hospital Corporation | Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing |
US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
EP2975942B1 (en) | 2013-03-21 | 2018-08-08 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
WO2014165825A2 (en) | 2013-04-04 | 2014-10-09 | President And Fellows Of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
WO2014172458A1 (en) | 2013-04-16 | 2014-10-23 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
JP6411463B2 (en) * | 2013-04-16 | 2018-10-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
US20160186208A1 (en) | 2013-04-16 | 2016-06-30 | Whitehead Institute For Biomedical Research | Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal |
EP2796558A1 (en) | 2013-04-23 | 2014-10-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants |
US10920192B2 (en) | 2013-04-23 | 2021-02-16 | Yeda Research And Development Co. Ltd. | Isolated naive pluripotent stem cells and methods of generating same |
CA2910427C (en) | 2013-05-10 | 2024-02-20 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
CN116083487A (en) | 2013-05-15 | 2023-05-09 | 桑格摩生物治疗股份有限公司 | Methods and compositions for treating genetic conditions |
US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
ES2883131T3 (en) | 2013-05-29 | 2021-12-07 | Cellectis | Methods for modifying T cells for immunotherapy using the RNA-guided CAS nuclease system |
JP7065564B2 (en) | 2013-05-29 | 2022-05-12 | セレクティス | Methods for Providing Accurate DNA Cleavage Using CAS9 Nickase Activity |
US20140359795A1 (en) | 2013-05-31 | 2014-12-04 | Recombinetics, Inc. | Genetic techniques for making animals with sortable sperm |
WO2014201015A2 (en) | 2013-06-11 | 2014-12-18 | The Regents Of The University Of California | Methods and compositions for target dna modification |
WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
EP3011034B1 (en) | 2013-06-17 | 2019-08-07 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
CN105492611A (en) | 2013-06-17 | 2016-04-13 | 布罗德研究所有限公司 | Optimized CRISPR-CAS double nickase systems, methods and compositions for sequence manipulation |
RU2716420C2 (en) | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Delivery and use of systems of crispr-cas, vectors and compositions for targeted action and therapy in liver |
AU2014281026B2 (en) | 2013-06-17 | 2020-05-28 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
WO2014204728A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
EP3011011A4 (en) | 2013-06-19 | 2017-05-31 | Sigma-Aldrich Co. LLC | Targeted integration |
JP2016528890A (en) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Therapeutic use of genome editing using the CRISPR / Cas system |
RU2764637C2 (en) | 2013-07-09 | 2022-01-19 | Президент Энд Фэллоуз Оф Харвард Коллидж | Multiplex genomic engineering guided by rna |
BR112016000571B1 (en) | 2013-07-10 | 2023-12-26 | President And Fellows Of Harvard College | IN VITRO METHODS FOR MODULATING EXPRESSION AND FOR ALTERING ONE OR MORE TARGET NUCLEIC ACIDS IN A CELL SIMULTANEOUSLY WITH REGULATING THE EXPRESSION OF ONE OR MORE TARGET NUCLEIC ACIDS IN A CELL AS WELL AS A YEAST OR BACTERIAL CELL COMPRISING NUCLEIC ACIDS |
US9663782B2 (en) | 2013-07-19 | 2017-05-30 | Larix Bioscience Llc | Methods and compositions for producing double allele knock outs |
US10563225B2 (en) | 2013-07-26 | 2020-02-18 | President And Fellows Of Harvard College | Genome engineering |
MX2016002118A (en) | 2013-08-22 | 2016-06-28 | Du Pont | Plant genome modification using guide rna/cas endonuclease systems and methods of use. |
US9925248B2 (en) | 2013-08-29 | 2018-03-27 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
WO2015040402A1 (en) | 2013-09-18 | 2015-03-26 | Kymab Limited | Methods. cells & organisms |
US10822606B2 (en) | 2013-09-27 | 2020-11-03 | The Regents Of The University Of California | Optimized small guide RNAs and methods of use |
WO2015052231A2 (en) | 2013-10-08 | 2015-04-16 | Technical University Of Denmark | Multiplex editing system |
CN105899665B (en) | 2013-10-17 | 2019-10-22 | 桑格摩生物科学股份有限公司 | The delivering method and composition being transformed for nuclease-mediated genome project |
WO2015068785A1 (en) | 2013-11-06 | 2015-05-14 | 国立大学法人広島大学 | Vector for nucleic acid insertion |
AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
US10787684B2 (en) | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
US10450586B2 (en) | 2013-11-28 | 2019-10-22 | Horizon Discovery Limited | Somatic haploid human cell line |
RU2685914C1 (en) | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Methods and compositions for genome targeted modification |
AU2014362248A1 (en) | 2013-12-12 | 2016-06-16 | Massachusetts Institute Of Technology | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
CN105899657A (en) | 2013-12-12 | 2016-08-24 | 布罗德研究所有限公司 | Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes |
KR20160089530A (en) | 2013-12-12 | 2016-07-27 | 더 브로드 인스티튜트, 인코퍼레이티드 | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
MX2016007328A (en) | 2013-12-12 | 2017-07-19 | Broad Inst Inc | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing. |
EP3080259B1 (en) | 2013-12-12 | 2023-02-01 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
CN106536729A (en) | 2013-12-12 | 2017-03-22 | 布罗德研究所有限公司 | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
JP6542226B2 (en) | 2013-12-13 | 2019-07-10 | セレクティス | A new method to select algal transformed cells using nucleases |
US9476065B2 (en) | 2013-12-19 | 2016-10-25 | Amyris, Inc. | Methods for genomic integration |
CN106133141B (en) | 2014-01-08 | 2021-08-20 | 哈佛学院董事及会员团体 | RNA-guided gene driving |
JP6479024B2 (en) | 2014-01-24 | 2019-03-06 | ザ チルドレンズ メディカル センター コーポレーション | High-throughput mouse model for antibody affinity optimization |
WO2015117041A1 (en) | 2014-01-30 | 2015-08-06 | Nair Ramesh B | Gene modification-mediated methods and compositions for generating dominant traits in eukaryotic systems |
US10233456B2 (en) | 2014-01-30 | 2019-03-19 | The Board Of Trustees Of The University Of Arkansas | Method, vectors, cells, seeds and kits for stacking genes into a single genomic site |
PL3105328T3 (en) | 2014-02-11 | 2020-10-19 | The Regents Of The University Of Colorado, A Body Corporate | Crispr enabled multiplexed genome engineering |
US10370680B2 (en) | 2014-02-24 | 2019-08-06 | Sangamo Therapeutics, Inc. | Method of treating factor IX deficiency using nuclease-mediated targeted integration |
EP3957735A1 (en) | 2014-03-05 | 2022-02-23 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
WO2015138510A1 (en) | 2014-03-10 | 2015-09-17 | Editas Medicine., Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
ES2821149T3 (en) | 2014-03-12 | 2021-04-23 | Prec Biosciences Inc | Deletion of the exon of the dystrophin gene by genetically modified nucleases |
RS65213B1 (en) | 2014-03-14 | 2024-03-29 | Cibus Us Llc | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair |
US9624498B2 (en) | 2014-03-18 | 2017-04-18 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
EP3122877B1 (en) | 2014-03-26 | 2023-03-22 | University of Maryland, College Park | Targeted genome editing in zygotes of domestic large animals |
GB201406968D0 (en) | 2014-04-17 | 2014-06-04 | Green Biologics Ltd | Deletion mutants |
KR101823661B1 (en) | 2014-04-24 | 2018-01-30 | 기초과학연구원 | A method of selecting a nuclease target sequence for gene knockout based on microhomology |
GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
WO2015173436A1 (en) | 2014-05-16 | 2015-11-19 | Vrije Universiteit Brussel | Genetic correction of myotonic dystrophy type 1 |
WO2015184268A1 (en) | 2014-05-30 | 2015-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods of delivering treatments for latent viral infections |
PL3152312T3 (en) | 2014-06-06 | 2020-08-10 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for modifying a targeted locus |
EP3674408A1 (en) | 2014-06-16 | 2020-07-01 | The Johns Hopkins University | Compositions and methods for the expression of crispr guide rnas |
MX2016017317A (en) | 2014-06-26 | 2017-08-24 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use. |
MA40253A (en) | 2014-07-15 | 2017-05-24 | Juno Therapeutics Inc | Engineered cells for adoptive cell therapy |
WO2016011428A1 (en) | 2014-07-17 | 2016-01-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating cells containing fusion genes |
US9944933B2 (en) | 2014-07-17 | 2018-04-17 | Georgia Tech Research Corporation | Aptamer-guided gene targeting |
EP3186376B1 (en) | 2014-08-27 | 2019-03-20 | Caribou Biosciences, Inc. | Methods for increasing cas9-mediated engineering efficiency |
EP3450558B1 (en) | 2014-08-27 | 2020-09-30 | New England Biolabs, Inc. | Synthon formation |
US10570418B2 (en) | 2014-09-02 | 2020-02-25 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification |
CA2957800A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector immune responses |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049024A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
WO2016054032A1 (en) | 2014-09-29 | 2016-04-07 | The Jackson Laboratory | High efficiency, high throughput generation of genetically modified mammals by electroporation |
WO2016054326A1 (en) | 2014-10-01 | 2016-04-07 | The General Hospital Corporation | Methods for increasing efficiency of nuclease-induced homology-directed repair |
AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
WO2016061073A1 (en) | 2014-10-14 | 2016-04-21 | Memorial Sloan-Kettering Cancer Center | Composition and method for in vivo engineering of chromosomal rearrangements |
US10428310B2 (en) | 2014-10-15 | 2019-10-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
CN107027313B (en) | 2014-10-17 | 2021-09-07 | 宾州研究基金会 | Methods and compositions for multiplex RNA-guided genome editing and other RNA techniques |
CN107208086A (en) | 2014-10-17 | 2017-09-26 | 霍华德休斯医学研究所 | genomic probe |
WO2016065364A1 (en) | 2014-10-24 | 2016-04-28 | Life Technologies Corporation | Compositions and methods for enhancing homologous recombination |
EP3215623A4 (en) | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
US11680268B2 (en) | 2014-11-07 | 2023-06-20 | Editas Medicine, Inc. | Methods for improving CRISPR/Cas-mediated genome-editing |
KR102531016B1 (en) | 2014-11-21 | 2023-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs |
US10883111B2 (en) | 2014-11-27 | 2021-01-05 | Danziger Innovations Ltd. | Nucleic acid constructs for genome editing |
US20170266320A1 (en) | 2014-12-01 | 2017-09-21 | President And Fellows Of Harvard College | RNA-Guided Systems for In Vivo Gene Editing |
EP3230452A1 (en) | 2014-12-12 | 2017-10-18 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
WO2016097751A1 (en) | 2014-12-18 | 2016-06-23 | The University Of Bath | Method of cas9 mediated genome engineering |
RU2707137C2 (en) | 2014-12-19 | 2019-11-22 | Регенерон Фармасьютикалз, Инк. | Methods and compositions for targeted genetic modification by single-step multiple targeting |
US10190106B2 (en) | 2014-12-22 | 2019-01-29 | Univesity Of Massachusetts | Cas9-DNA targeting unit chimeras |
WO2016108926A1 (en) | 2014-12-30 | 2016-07-07 | The Broad Institute Inc. | Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis |
WO2016112242A1 (en) | 2015-01-08 | 2016-07-14 | President And Fellows Of Harvard College | Split cas9 proteins |
CN107406842B (en) | 2015-01-09 | 2021-05-11 | 生物辐射实验室股份有限公司 | Detecting genome editing |
WO2016114972A1 (en) | 2015-01-12 | 2016-07-21 | The Regents Of The University Of California | Heterodimeric cas9 and methods of use thereof |
WO2016115326A1 (en) | 2015-01-15 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating genome editing |
ES2955957T3 (en) | 2015-01-28 | 2023-12-11 | Caribou Biosciences Inc | CRISPR hybrid DNA/RNA polynucleotides and procedures for use |
WO2016130697A1 (en) | 2015-02-11 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Methods and kits for generating vectors that co-express multiple target molecules |
CN107532182A (en) | 2015-02-23 | 2018-01-02 | 克里斯珀医疗股份公司 | Treat the material and method of hemoglobinopathy |
WO2016135559A2 (en) | 2015-02-23 | 2016-09-01 | Crispr Therapeutics Ag | Materials and methods for treatment of human genetic diseases including hemoglobinopathies |
US11261466B2 (en) | 2015-03-02 | 2022-03-01 | Sinai Health System | Homologous recombination factors |
GB201504223D0 (en) | 2015-03-12 | 2015-04-29 | Genome Res Ltd | Biallelic genetic modification |
WO2016154579A2 (en) | 2015-03-26 | 2016-09-29 | Editas Medicine, Inc. | Crispr/cas-mediated gene conversion |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
-
2014
- 2014-10-15 RU RU2016126989A patent/RU2685914C1/en active
- 2014-10-15 US US14/515,503 patent/US9546384B2/en active Active
- 2014-10-15 MX MX2016007654A patent/MX2016007654A/en unknown
- 2014-10-15 KR KR1020177023915A patent/KR102170502B1/en active IP Right Grant
- 2014-10-15 RU RU2019111616A patent/RU2725520C2/en active
- 2014-10-15 AU AU2014360811A patent/AU2014360811B2/en active Active
- 2014-10-15 BR BR112016013400-1A patent/BR112016013400B1/en active IP Right Grant
- 2014-10-15 CN CN201480074803.XA patent/CN105980568B/en active Active
- 2014-10-15 WO PCT/US2014/060788 patent/WO2015088643A1/en active Application Filing
- 2014-10-15 CA CA2933433A patent/CA2933433C/en active Active
- 2014-10-15 SG SG10201700961TA patent/SG10201700961TA/en unknown
- 2014-10-15 CN CN201911060314.XA patent/CN110951779B/en active Active
- 2014-10-15 KR KR1020167018610A patent/KR101773782B1/en active IP Right Grant
- 2014-10-15 JP JP2016538790A patent/JP6174811B2/en active Active
- 2014-12-19 US US14/578,291 patent/US9228208B2/en active Active
-
2015
- 2015-10-30 US US14/928,180 patent/US20160060657A1/en not_active Abandoned
-
2016
- 2016-05-17 IL IL245674A patent/IL245674B/en active IP Right Grant
- 2016-06-10 MX MX2021014368A patent/MX2021014368A/en unknown
- 2016-07-27 JP JP2016147146A patent/JP6517755B2/en active Active
- 2016-11-17 US US15/354,270 patent/US10208317B2/en active Active
-
2017
- 2017-08-07 AU AU2017210669A patent/AU2017210669B2/en active Active
-
2018
- 2018-12-18 US US16/224,413 patent/US10711280B2/en active Active
-
2019
- 2019-03-28 AU AU2019202160A patent/AU2019202160B2/en active Active
- 2019-04-18 JP JP2019079554A patent/JP6670412B2/en active Active
-
2020
- 2020-06-03 US US16/891,978 patent/US11820997B2/en active Active
-
2023
- 2023-10-11 US US18/484,777 patent/US20240052365A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277196A (en) | Methods and compositions for genome engineering | |
IL245674B (en) | Methods and compositions for the targeted modification of a genome | |
HRP20211385T8 (en) | Targeted modification of rat genome | |
IL272193B (en) | Genome engineering | |
IL269461B (en) | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | |
HK1223401A1 (en) | Methods and compositions for treatment of a genetic condition | |
HRP20181632T1 (en) | Methods and compositions for the targeted modification of a genome | |
EP2981334A4 (en) | Compositions and methods for inhibiting viral activity |